GeoVax Prioritizes GEO-MVA and Gedeptin, Discontinues COVID-19 Vaccine Development

GeoVax Labs, Inc. (Nasdaq: GOVX) announced a strategic portfolio prioritization to concentrate resources on its lead programs, GEO-MVA and Gedeptin, while discontinuing active development of its GEO-CM04S1 COVID-19 vaccine candidate. The decision, driven by the evolving global COVID-19 vaccine market and a focus on programs with clearer regulatory pathways and commercialization potential, marks a pivotal shift for the clinical-stage biotechnology company.

GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, is advancing under an expedited regulatory pathway supported by European Medicines Agency (EMA) scientific advice. This pathway could enable approval based on a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine, significantly accelerating development timelines. GeoVax has manufactured and released clinical-grade material for the planned Phase 3 study, expected to initiate in the second half of 2026. The company has also initiated outreach with global procurement and preparedness stakeholders, including government agencies and biodefense programs, to support potential vaccine supply agreements for national stockpiling and outbreak response. This positions GEO-MVA as a critical additional supplier for supply-chain resilience and biodefense preparedness.

In oncology, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) platform, in alignment with emerging immuno-oncology treatment paradigms. The planned Phase 2 study (AdPNP-203) will evaluate Gedeptin in combination with pembrolizumab and fludarabine in a neoadjuvant setting for head and neck cancers, aiming to enhance tumor immune visibility and improve clinical outcomes. Gedeptin's mechanism involves localized generation of a potent chemotherapeutic agent that damages treated lesions and sensitizes tumors to checkpoint inhibitors by exposing neoantigens, potentially expanding response rates in patients who derive limited benefit from checkpoint inhibition alone. This approach aligns with the landmark KEYNOTE-689 trial results demonstrating improved event-free survival with neoadjuvant checkpoint inhibitor therapy.

David Dodd, Chairman and CEO, stated, "GeoVax is at an important inflection point, and this decision reflects a deliberate and disciplined focus on the programs we believe can deliver the greatest near-term and long-term value." The discontinuation of the COVID-19 vaccine program was not related to safety concerns but to the contraction of the global COVID-19 vaccine market. GeoVax emphasized that portfolio prioritization is standard in biotechnology, enabling alignment of resources with highest-value opportunities.

The strategic shift underscores GeoVax's commitment to focused execution toward late-stage development and commercialization. With GEO-MVA poised for potential Emergency Use Licensing and Gedeptin gaining relevance in evolving oncology treatments, the company aims to create long-term value for stakeholders.